Express News | Fuan Pharmaceutical: A subsidiary has received the pharmaceutical registration certificate for midazolam hydrochloride oral solution.

BreakingsFeb 10 15:57

Express News | Fuan Pharmaceutical: Subsidiary Qingyutang's Metformin and Empagliflozin Tablets have obtained the pharmaceutical registration certificate.

BreakingsJan 9 16:05

Fuan Pharmaceutical (300194.SZ): There are multiple cephalosporin series antibiotic products in production and sales.

On January 8, Gelonghui reported that Fuan Pharmaceutical (300194.SZ) stated on the investor interaction platform that the company has multiple cephalosporin series antibiotic products in production and sale, including injectable ceftazidime, cefoperazone sodium, cefmetazole sodium, and cefepime sodium sulbactam sodium, among others.

Gelonghui FinanceJan 8 16:10

Fuan Pharmaceutical (300194.SZ): The subsidiary's injectable cefoperazone sulbactam sodium and other cephalosporin antibiotics can all be used to treat pneumonia.

On January 8, Gelonghui reported that Fuan Pharmaceutical (300194.SZ) stated on the investor interaction platform that the company's subsidiary's injectable medications, Cefuroxime Sodium, Cefotaxime, and Ceftazidime/Avibactam, can all be used to treat pneumonia.

Gelonghui FinanceJan 8 16:07

Fuan Pharmaceutical (300194.SZ): has the approval for the Against Influenza drug Peramivir injection, but currently does not have production or sales.

On December 23, Gelonghui reported that Fuan Pharmaceutical (300194.SZ) stated on the investor interaction platform that the company has received approval for the anti-influenza drug Peramivir injection, but it is currently not in production or on sale.

Gelonghui FinanceDec 23, 2024 17:07

Fuan Pharmaceutical (300194.SZ): A subsidiary has withdrawn the pharmaceutical registration application for acetylcysteine injection.

Globe Union reported on December 23 that Fuan Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary, Fuan Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd. (hereinafter referred to as "Qingyutang"), recently received a "Notice of Termination of Drug Registration Application" issued by the National Medical Products Administration. The indication for the application of acetylcysteine injection was for the treatment of acetaminophen overdose. Affected by market changes and other factors, after careful research and in conjunction with the company's R&D strategy, the company decided to voluntarily withdraw this registration application.

Gelonghui FinanceDec 23, 2024 16:54